A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Gemcabene (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Acronyms INDIGO-1
- Sponsors Gemphire Therapeutics; NeuroBo Pharmaceuticals
- 30 Mar 2020 Status changed from active, no longer recruiting to completed.
- 28 Jun 2018 Results presented in the Gemphire Therapeutics media release.
- 28 Jun 2018 Primary endpoint has been met. (Change in fasting triglycerides from Baseline (Day 1) to Week 12 (Day 84)), according to a Gemphire Therapeutics media release.